SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001445305-14-002058
Filing Date
2014-05-09
Accepted
2014-05-09 14:07:15
Documents
11
Period of Report
2014-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q navb0331201410q.htm 10-Q 558239
2 EXHIBIT 31.1 navb03312014ex31-1.htm EX-31.1 9913
3 EXHIBIT 31.2 navb03312014ex31-2.htm EX-31.2 9910
4 EXHIBIT 32.1 navb03312014ex32-1.htm EX-32.1 5165
5 EXHIBIT 32.2 navb03312014ex32-2.htm EX-32.2 5214
  Complete submission text file 0001445305-14-002058.txt   3658397

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20140331.xml EX-101.INS 386927
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT navb-20140331.xsd EX-101.SCH 28176
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT navb-20140331_cal.xml EX-101.CAL 48594
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT navb-20140331_def.xml EX-101.DEF 128430
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT navb-20140331_lab.xml EX-101.LAB 416956
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT navb-20140331_pre.xml EX-101.PRE 237250
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 14828315
SIC: 2835 In Vitro & In Vivo Diagnostic Substances